What patient assessment skills do pharmacist independent prescribers require to prescribe immunomodulators in myeloma?

Author:

Slavin Anton12ORCID,Kurdi Amanj34,Wilson Mandy1

Affiliation:

1. Edinburgh Cancer Centre, NHS Lothian, Edinburgh, UK

2. Pharmacy, Western General Hospital, Edinburgh, UK

3. Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK

4. Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq

Abstract

Aim To gain consensus on the patient assessment skills required by pharmacist independent prescribers prescribing immunomodulators in myeloma across National Health Service Scotland. Methods This was a two-phase study which used nominal group technique to gain local consensus followed by a two-round eDelphi questionnaire to gain national consensus across all cancer networks. Setting This project was conducted across the three cancer networks within NHS Scotland: South East Scotland Cancer Network; West of Scotland Cancer Network and North Cancer Alliance. Subjects Participants were invited from each cancer network (South East Scotland Cancer Network, West of Scotland Cancer Network and North Cancer Alliance) and included haematology consultants, haematology specialist registrars, haematology advanced nurse practitioners and haematology pharmacists. Results There were five participants in the nominal group technique. Twenty-two out of 31 patient assessment skills gained local consensus, seven patient assessment skills did not gain consensus and two patient assessment skills were deemed irrelevant. There were 12 and 14 participants in round one and two of the eDelphi questionnaire, respectively. Twenty-nine patient assessment skills were included in the first-round questionnaire and 21 gained consensus. The remaining eight patient assessment skills were included in round two where seven did not achieve consensus and one achieved disagreement consensus. Conclusion This research outlines 21 patient assessment skills required for pharmacist independent prescribers to prescribe immunomodulators for myeloma patients according to haematology specialists in Scotland. Discussion on patient assessment skills without consensus showed that the pharmacist independent prescribers would have a shared responsibility with the consultant. This work should inform the development of a competency framework to allow training of pharmacist independent prescribers in Scotland. Some patient assessment skills could be transferrable for pharmacist independent prescribers prescribing systemic anti-cancer therapy for other haematological malignancies.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Reference38 articles.

1. The Scottish Medicines Consortium. SMC2289 4th September 2020. https://www.scottishmedicines.org.uk/media/5466/lenalidomide-revlimid-mm-final-september-2020-for-website.pdf (2020, accessed 20th October 2020).

2. Myeloma UK. What is myeloma? https://www.myeloma.org.uk/understanding-myeloma/what-is-myeloma/ (2020, accessed 01 December 2020).

3. Cancer Research UK. Myeloma statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma (2020, accessed 01 December 2020).

4. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

5. British Oncology Pharmacist Association and Faculty of Cancer Pharmacy. Oncology pharmacy non-medical prescribing guidelines (Version 4.1). www.bopawebsite.org/sites/default/files/publications/BOPA%20Non%20Medical%20Prescribing%20Guidelines%20v4.1%20Aug%202018.pdf (2018, accessed 7th November 2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3